Results from @alzassociation.bsky.social’s U.S. POINTER lifestyle intervention trial were named to @jama.com’s Research of the Year roundup—recognizing its rigor and relevance for clinicians and health systems advancing evidence-based dementia risk reduction. #JAMAROTY25 ja.ma/4j3tdar

New real-world data from ALZ-NET shared for the first time at #CTAD25 shows outcomes on FDA-approved anti-amyloid therapies are consistent with clinical trials, with stable cognition/function and expected ARIA rates. Learn more: www.alz.org/news/2025/al...

Three add-on studies find U.S. POINTER lifestyle intervention improved blood pressure regulation of blood flow to the brain, reduced sleep apnea respiratory events & increased cognitive resilience for adults with certain Alzheimer’s-related brain changes. bit.ly/3MiCTBy

The evoke & evoke+ clinical trials testing an oral semaglutide pill to treat early Alzheimer’s did not demonstrate a statistically significant reduction in disease progression. 

While we’re disappointed in the results, these studies provide valuable insights to guide future research. bit.ly/3M0OTaH

The FDA has cleared the first blood test for Alzheimer’s for use in primary care settings to rule out the presence of amyloid.

“This is another important step toward expanding access to Alzheimer’s diagnostic tools."-Joanne Pike, Association president & CEO

Read our full statement: bit.ly/4oh3Tiu.

🚨 Headed to #AAFPFMX in Anaheim (Oct 5–9)? Come find us at Booth 857! 🎉

We’ll be sharing how ALZPro + the Alzheimer’s Association support family physicians with evidence-based tools and resources for frontline care.

👉 Details + registration: i.snoball.it/p/JLpaJ/l/1

Calling all health care professionals: your new go-to resource is here. 🩺📚

ALZPro gives you centralized access to the latest science and practice tools—from clinical guidelines to continuing education to care pathways and more.

Learn more: alz.org/ALZPro

ALZPro was created to empower professionals like you to reduce risk, advance early detection, improve care and expand equitable access.

Explore this new resource from @alzassociation.bsky.social to stay ahead in the fast-changing landscape of dementia care.

Learn more: alz.org/ALZPro

Care professionals: Navigate care with confidence. From care planning and risk reduction to navigation and caregiver support, ALZPro helps you deliver high-quality, compassionate services across settings and stages.
Learn more: alz.org/alzpro
#DementiaCare

Health care professionals: thank you for attending AAIC For All to hear the latest in Alzheimer’s treatment, prevention & care.

➡️ Next up: Explore ALZPro—the Association’s new hub that centralizes the tools you need. alz.org/ALZPro

#AAIC25 @alzpro.bsky.social

Health care professionals: ALZPro is your gateway to the latest science and practice resources from @alzassociation.bsky.social. Whether you're providing care, conducting research, or building better systems, ALZPro helps you stay informed and connected.
alz.org/ALZPro

#AAIC25 #ALZsky

Researchers: Accelerate discovery & grow your impact.

ALZPro is a new centralized hub from @alzassociation.bsky.social connecting you with funding opportunities, publication channels, data tools, and research networks to advance dementia science.

Learn more: alz.org/alzpro
#AAIC25 #ALZSky

#AAIC25 attendees: Want more info on ALZPro? Visit our team at Booth 1010 in the Exhibit Hall to discover how this new professional hub offers essential resources, and follow @alzpro.bsky.social for future updates.

Meet ALZPro.

Health care professionals & researchers, this centralized hub from the @alzassociation.bsky.social is your single point of access for the latest science and practice tools. Stay current, connect with peers, and deliver better care.

➡️Start exploring: alz.org/alzpro